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Background: Carboplatin based regimens have demonstrated activity in pediatric
patients with low grade gliomas (LGG). However, carboplatin hypersensitivity reactions
(CHRs) may be a major problem leading to premature cessation of an effective therapy.
The objectives of this study were to describe the prevalence, characteristics and
management of CHR.
Methods: We performed a retrospective review of children with LGG treated between
January 1994 and July 2015 with carboplatin and vincristine who had a documented
CHR. We identified two groups: the first was treated following the schema proposed by
Packer et al., and re-exposed to carboplatin using a desensitization protocol; the second
was treated according to protocol SIOP LGG 2004 and re-exposed with the infusion time
prolonged.
Results: CHRs were observed in 16 patients (34%) out of 47. Hypersensitivity reactions
occurred in 6 patients (20.7%) of the first, and 10 patients (55.5%) of the second group,
respectively. The grade 2 reactions were the most common. The median number of
carboplatin doses administered at the first episode of CHR was 7 (range, 3–9) for the first
group, and 8.5 (range, 5–11) for the second, respectively. Six patients were re-exposed
to carboplatin using a desensitization protocol; 10 with a prolonged infusion time. Overall
success rate for re-exposition was 43.75% (100% and 10%, respectively) (P = 0.001).
Conclusions: Our results show that re-exposure is a safe alternative to abandoning
carboplatin. Desensitization showed greater effectiveness compared to a prolonged
infusion time, which allowed the patients to receive effective treatment without adverse
reactions.
Keywords: carboplatin, hypersensitivity, re-exposition, children, low grade glioma
INTRODUCTION
Low-grade glial tumors are the most common brain tumors of childhood (Packer et al., 2008). The
primary treatment modality is surgery while chemotherapy and radiotherapy have been reserved
for recurrent and progressive cases with deterioration of visual or pituitary function (Trisciuzzi
et al., 2004). Carboplatin, usually given with vincristine, is one of the front-line treatments for
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pediatric low-grade gliomas (LGG) (Packer et al., 1993). The
combination is associated with a 5-year event-free survival of
39% in sporadic, and 69% in neurofibromatosis type 1 (NF1)-
associated LGG (Ater et al., 2016). Other combination regimens,
such as thioguanine, procarbazine, lomustine, and vincristine,
cisplatin/etoposide, bevacizumab/irinotecan and temozolomide
have produced consistent, durable responses (Packer et al.,
1997; Massimino et al., 2010) but each of these therapies
has drawbacks which include late toxicities such as second
malignant neoplasms, infertility, vasculopathy/stroke or toxicity
due to concomitant therapies (Ruggiero et al., 2010) as well as
concerns that the efficacy of these other options is no better
than the first line regimen (Bowers et al., 2006; Eichenauer et al.,
2014).
Currently, the combination vincristine/carboplatin is themost
widely adopted multi-agent chemotherapy for childhood LGG
(Perilongo, 2005). However, one of the most common side
effects leading to premature treatment cessation is carboplatin
hypersensitivity reaction (CHR). The frequency of CHRs has
been reported to be 7–78% while the median number of
administered carboplatin doses at the first reaction ranges
between 7 and 9 (Lazzareschi et al., 2002; Gnekow et al., 2004).
Management options include cessation of carboplatin and
switching to another agent, premedication with antihistamines
and/or corticosteroids, and carboplatin desensitization. The
reported success rate for completion of chemotherapy in children
after various modifications ranges between 0 and 75%, but
previous studies were generally either performed on small groups
or reported from multiple centers with different management
strategies (Broome et al., 1996; Ogle et al., 2002; Gnekow et al.,
2004; Lafay-Cousin et al., 2005).
The aim of this study is to summarize the incidence and the
clinical features of CHRs occurring in children with LGG treated
with carboplatin and vincristine and their impact on treatment
efficacy, in order to outline possible adequate prevention and
management strategies.
PATIENTS AND METHODS
Study Population
This retrospective study included 47 children with LGG aged 1–
18 years, who were treated with carboplatin and vincristine at
the Pediatric Oncology Division of the Catholic University of
Rome between January 1994 and July 2015. The median age of
the patients was 3.4 years (range, 1–16), 25 males (53.2%), and 22
females (46.8%). Six patients (12.7%) had LGG associated with
NF1. The tumors were located in diencephalon in 36 children
(76.5%); other locations included the spinal cord, brainstem,
cerebral hemisphere and isolated optic nerve (Table 1).
Two populations were identified: the first consisting of
29 children, treated from 1994 to 2003 with carboplatin
and vincristine according to Packer et al. (1997); the second
consisting of 18 children treated from 2004 to 2015 according
Abbreviations: LGG, low grade gliomas; CHR, carboplatin hypersensitivity
reaction; NF1, neurofibromatosis type 1.
to protocol SIOP LGG 2004. The population treated according
to Packer et al. received a combination of vincristine 1.5 mg/m2
and carboplatin 175 mg/m2 on a weekly schedule. The induction
course consisted of carboplatin at a dose of 175 mg/m2/week
for 4 consecutive weeks, followed by 2 weeks rest period and
again carboplatin for 4 weeks. Vincristine at a dose of 1.5
mg/m2 was given by intravenous bolus weekly for 10 weeks
concurrently with carboplatin. Maintenance therapy consisted
of at least eight cycles. Each cycle included 4 weekly doses of
carboplatin at 175 mg/m2/week and 3 weekly doses of vincristine
at 1.5 mg/m2/week (given concomitantly with the first 3 weeks
of carboplatin), followed by 2 weeks of rest for a total of 6
weeks. Population treated according to protocol SIOP LGG 2004
received a combination of vincristine 1.5 mg/m2 (max 2 mg)
and intravenous 1 h infusion of carboplatin at a dose of 550
mg/m2. Induction standard consisted in a weekly regimen of
vincristine and carboplatin every 3 weeks for 10 weeks. Following
the 10 week-induction treatment the combination of vincristine
and carboplatin was given three times at 4-weekly intervals.
Consolidation was achieved by the continuous, simultaneous
application of vincristine and carboplatin. However, treatment
was prolonged up to week 81 by extending treatment intervals
to 6 weeks, and vincristine was given at a more intense schedule
on day 1, 8, and 15 of each cycle. All patients received
antiemetic ondansetron before carboplatin infusion. Carboplatin
was administered, in both treatments, in 1-h infusions in
saline solution. The severity of allergic reactions was evaluated
according to the toxicity scale used by the National Cancer
Institute1(CTCAE, v4.0). Intradermal testing was performed in
15 patients according to the generally applied techniques on
the volar surface of the forearm. In particular, the prick test
and intradermal skin tests were performed with carboplatin at a
concentration of 1 mg/ml; the pacth test was performed utilizing
10 mg/ml of carboplatin.
This retrospective study was approved by the Ethics
Committee of the Sacred Heart Catholic University.
Treatment after CHR
The institutional clinical practice for most patients with a LGG
and a carboplatin CHR was to attempt re-exposure. Patients
treated with the schedule according to Packer et al., were re-
exposed using the desensitization protocol by Lazzareschi et al.
(2002) which consists of a standard dose of carboplatin (175
mg/m2 in 100 ml saline solution) at an increasing infusion
rate as follows: 0.3 mg/m2/min for 30min, 0.6 mg/m2/min for
30min, 1.8 mg/m2/min for 30min, and 2.4 mg/m2/min for
30min (Table 2). Children treated following protocol SIOP LGG
2004 were re-exposed, according to protocol guidelines, using
prolonged infusion time (4 h).
The clinical characteristics evaluated in the study were age,
gender, histopathology, and anatomic location of the tumor,
presence of NF1, type and time of onset CHR, type of
modification in case of CHR, and outcome (continuation or
discontinuation of carboplatin therapy after rechallenge).
1National Cancer institute, Common Terminology Criteria for Adverse Evens v4.0,
NCI, NIH, DHHS. May 29, 2009. NIH publication # 09-7473.
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TABLE 1 | Patients’ clinical and pathological characteristics.
Patients characteristics CHR status No. patients (%)
CHR positive,
N = 16
CHR negative,
N = 31
Median age at diagnosis of LLG
months (range)
34 (12–72) 53.5 (12–156)
NF1 2 (12.5) 5 (16.1)
Boys/girls 8/8 14/17
Diencephalic location 13 (81.2) 24 (77.4)
Monthly carboplatin administration 10 (62.5) 8 (25.8)
Weekly carboplatin administration 6 (37.5) 23 (74.2)
TABLE 2 | Carboplatin desensitization protocol.
Infusion rate (mg/m2/min) Time (min)
0.3 30
0.6 30
1.2 30
1.8 30
2.4 30
After the frequency of CHR was described, Fisher’s exact test
or chi-square analysis were used to assess the potential predicting
factors of CHR. Mann-Whitney U-test was used to compare the
independent groups. Statistical significance was considered as a
P < 0.005. STATA 14 for Windows program was used for all
statistical analyses.
RESULTS
All 47 patients were eligible for our study. Sixteen (34%)
children were identified as having a CHR; 6 (20.7%) occurred
in the group treated according to Packer et al., and 10 (55.5%)
occurred in the group treated according to protocol SIOP
LGG 2004. Age of patients ranged between 12 and 72 months
at the time of the reaction to carboplatin. Fifteen children
had juvenile pilocytic astrocytoma and one child had fibrillary
astrocytoma.
The median number of carboplatin doses administered at the
first episode of CHR was 8 (range, 3–11).
CHR occurred earlier during the weekly schedule with
a median of 7 infusions (range, 3–9) and with a median
cumulative dose of 1,225 mg/m2 (range, 525–1,575 mg/m2)
compared with a median of 8.5 infusions (range, 5–11) and a
median cumulative dose of 4,675 mg/m2 (range, 2,750–6,050
mg/m2) on the monthly schedule. The occurrence of CHR
was not related to a specific cumulative dose of carboplatin
(P > 0.7). The cumulative incidence of CHR appeared to
increase with the number of infusions without any plateau effect
(P < 0.04).
Of the 16 children who developed CHR, the severity of
the reaction was grade 1 in 2 patients, grade 2 in 12 patients
TABLE 3 | Patients’ characteristics with CHRs.
Patients
characteristics
Treatment schedule
Protocol by Packer et al.,
N = 6
Protocol SIOP LGG 2004,
N = 10
Boys/girls 4/2 4/6
Median age at reaction
months (range)
20 (12–60) 39.5 (12–72)
Median No. of infusion
(range)
7 (3–9) 8.5 (5–11)
Median cumulative dose
(mg/m2)
1225 (525–1,575) 4675 (2,750–6,050)
Grade CHR 1-2 5 (83.6) 9 (90)
Grade CHR 3 1 (16.4) 1 (10)
and grade 3 in 2 patients according to the National Cancer
Institute. There were no grade 4 allergic reactions (Table 3).
The patients who developed grade 3 bronchospasm were
treated with hydrocortisone and adrenalin and symptoms were
resolved within 1 h. Chlorphenamine and hydrocortisone were
administered intravenously to patients with grade 2 reactions
with rapid recovery.
Among the 16 patients who developed CHR, all patients
were re-exposed to carboplatin: 6 with desensitization, and 10
prolonging the infusion time according to SIOP LGG 2004
guidelines. The median interval between CHR and rechallenge
was 21 days (range, 8–114). There were no significant differences
in gender, NF1 status, mean age at treatment initiation, or tumor
location between the patients who were re-exposed to carboplatin
using a prolonged infusion time or alternatively a desensitization
protocol.
There was difference in the success of carboplatin rechallenge
between the patients who were treated by prolonging the infusion
time only (1 of 10, or 10% successfully rechallenged) compared to
those who underwent a desensitization protocol (6 of 6, or 100%
successfully rechallenged) (P = 0.001).
Of the 10 patients who received post CHR with prolonged
infusion time 9 patients discontinued carboplatin because of
either recurrent same grade CHR or because of progression to
a higher grade CHR (6 and 3 patients, respectively). Patients
who failed carboplatin rechallenge received a median of 9
doses at the first reaction (range, 5–11), and a median of 2
doses post rechallenge, at the second reaction (range, 1–8)
(Table 4).
Of 47 cases, 5 (10.6%) were deceased, resulting in 10 and 20
years OS of 89 and 82%, respectively. Thirty-seven percent of
the population experienced at least 1 progression of the primary
tumor, while 17% had multiple tumor progression events. The
10 and 20-year PFS was 61 and 52, 8%, respectively. Among
the 7 patients continuing on chemotherapy with carboplatin
(after desensitization protocol in 6 patients and prolonging
infusion time in 1 patient), there was observed to be: 1
complete response, 2 partial responses, 2 stable disease and 2
progressive disease (20-year OS = 85.7%, and 20-year PFS =
57.2%).
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DISCUSSION
A number of cytotoxic agents are known to cause severe
allergic reactions leading to treatment discontinuation. The use
of carboplatin in the treatment of children with brain tumors
is associated with hypersensitivity reactions. The incidence of
allergic reactions varies according to the different schedules of
carboplatin, ranging between 7 and 78% (Chang et al., 1995;
Schiavetti et al., 1999; Mahoney et al., 2000; Demaerel et al.,
2002; Lazzareschi et al., 2002). Yu et al. identified the weekly
dosing schedules of carboplatin as a risk factor for allergic
reaction in brain tumor patients (Yu et al., 2001). The risk
of hypersensitivity appears to increase with repeated exposure
to carboplatin, generally after several courses of therapy. This
could explain the higher prevalence of allergic reaction recorded
in specific patients treated with protocols that use a repeated
cycle of carboplatin. In contrast with the experience reported
by Yu et al. (2001), we found that patients receiving weekly
dosing had an incidence of CHR no greater than patients
on the 3 weekly carboplatin protocol. However, reactions
occurred 6 months earlier in the weekly dosing group (2.1
vs. 8 months after treatment initiation, respectively). The exact
mechanism of carboplatin hypersensitivity is neither adequately
known nor exhaustively elucidated (Chiaretti et al., 2004).
Hypersensitivity reactions have been reported to all platinum
containing chemotherapeutics (Makrilia et al., 2010; Ruggiero
et al., 2013b). Various immunological and non-immunological
mechanisms can be involved in the pathogenesis of HSRs.
A type IgE mediated hypersensitivity is supported by the
rising incidence of hypersensitivity with repeated doses, and
the occurrence of positive skin prick test reactions to platinum
compounds (Leguy-Seguin et al., 2007).
Most mild reactions seem to caused by alternative mechanism
of hypersensitivity non IgE mediated, or rather mast cells and
basophil activation with direct release of histamine or cytokine.
In support of this mechanism for hypersensitivity is the fact
that the reactions often occur midway through infusions of
carboplatin rather than at the start, as expected for IgE mediated
reactions. In our cohort, reactions occurred within minutes after
initiation of the infusion or midway through the infusion or
else at the end of infusion or several hours after the drug was
delivered. This differs from the typical IgE mediated sensitivity
and also intradermal prick tests to carboplatin appear not to
be conclusive. There may, in fact, be a combination of the
two mechanisms. The lack of sensitivity of skin tests could be
accounted for by the low molecular weight of carboplatin which
is not immunogenic in its native form.
The results from this retrospective study demonstrate the
increased effectiveness of the desensitization protocol compared
with the prolonging of the infusion time for continued treatment
with carboplatin after an HSR.
Overall, we noted 43.75% of patients were successfully re-
exposed to carboplatin (100% for the group re-exposed using
a desensitization protocol, and 10% for the group treated by
prolonging infusion time), 56% failed the rechallenge. Recently,
Lax et al. reported that extended carboplatin infusion does not
reduce frequency of hypersensitivity reaction in the retreatment
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of patients with recurrent platinum-sensitive cancer (Lax et al.,
2017).
Moreover, as suggested by various authors, premedication
with anti-histamines and/or corticosteroids is able to prevent an
allergic reaction only in a limited number of patients with mild
or moderate reactions. Moreover, the prolonged use of steroids is
associated with long term side effects in children and adolescents,
such as mood changes, weight gain and osteoporosis (Ruggiero
et al., 2013a). The success of re-exposure in the studies that have
used only premedication was between 0 and 28% (Genc et al.,
2012).
We used a protocol of desensitization only on the progressive
infusion rate with subsequent prolonging of the infusion time
of carboplatin without premedication. The use of small starting
doses with a progressive increase is thought to consume an
IgE antibody and slowly avoid an acute reaction (CTCAE,
v4.0). Prolonging infusion time also allows chemotherapy agent
antigens to be delivered in a less concentrated fashion per
unit of time and therefore decreases antigenic exposure. The
protocol was well tolerated and allowed patients to be treated
with response to carboplatin.
In our study, an increased severity of CHR on re-exposure was
recorded in 3 patients. The increased severity of hypersensitivity
re-exposure reactions might subject the patients to the risk of
anaphylaxis. Therefore, the benefits of continuing carboplatin
chemotherapy should be carefully weighed against the risk of
potential hazards.
Some authors have tried to detect predictive factors for
CHR (Markman et al., 2003a,b). Currently, there is no accurate
predictive factor to identify which patients will truly benefit from
altering CHR techniques, and no definitive recommendations
can be drawn from our experience. Our results suggest that
desensitization protocol is more effective than the extension of
the infusion time. The success of re-exposure with desensitization
protocol in our study was 100%. Literature data show a success
of desensitization between 20 and 75%. This difference could be
due to the different patterns of desensitization used. The main
variables influencing the success of re-exposure appear to be: the
starting dose, the infusion rate and the number of increments
(Lafay-Cousin et al., 2005; Ruggiero et al., 2013a; Dodgshun et al.,
2016; Shah et al., 2016). A lower starting dose, a slow infusion,
and a number of increments greater than or equal to 4, are
associated with a greater probability of success.
In conclusion, patients responding to carboplatin
chemotherapy might be good candidates for carboplatin
chemotherapy even when a CHR occurs. Carboplatin has proven
efficacy and a low toxicity profile; termination of the therapy at
the first episode of CHR does not seem justified; a desensitization
protocol should be considered for patients sensitive to treatment
with carboplatin in order to avoid the discontinuation of an
effective chemotherapy and improve their chances of cure.
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